Femasys Inc.
Femasys Inc. (Nasdaq: FEMY) develops and commercializes women’s health medical devices, with products addressing infertility, permanent birth control, fallopian-tube assessment and cervical cancer diagnosis. Its infertility portfolio includes FemaSeed, an FDA-cleared intratubal insemination device that delivers sperm… From the company’s description.
Over the twelve months to Jun 30, 2026, Femasys Inc. reported revenue of $2.30M, up 21.8% from a year earlier, and a net loss of $11.77M. Its operating margin was −764.1%, and operations used $17.65M in cash. In fiscal 2025, it reported revenue of $2.29M, up 40.8% from fiscal 2024, and a net loss of $18.63M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Femasys Inc. does
In the company’s own words
Femasys Inc. (Nasdaq: FEMY) develops and commercializes women’s health medical devices, with products addressing infertility, permanent birth control, fallopian-tube assessment and cervical cancer diagnosis. Its infertility portfolio includes FemaSeed, an FDA-cleared intratubal insemination device that delivers sperm toward the fallopian tube, FemVue and FemCath diagnostic devices, and FemSperm kits for in-office sperm preparation and analysis. FemBloc is a non-surgical permanent birth control system, paired with FemChec for ultrasound confirmation; it is approved in Europe, the UK and New Zealand and remains in clinical development for U.S. approval. FemCerv is an endocervical tissue sampler. The company sells to healthcare practitioners, including gynecologists and reproductive endocrinologists, and uses distribution partners in some international markets. Its products are manufactured or assembled at its own facility. The portfolio is organized around reproductive health solutions, rather than disclosed reportable segments. As of December 31, 2025, Femasys held 228 issued patents globally. Its website is www.femasys.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- SUWANEE, GA
- Fiscal year end
- December
- CIK
- 1339005
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Femasys Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Femasys Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Femasys Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Femasys Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Femasys Inc.'s last four quarterly filings that the numbers alone won't show?”